Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Breast Neoplasms 256Carcinoma, Non-Small-Cell Lung 212Ovarian Neoplasms 134Lung Neoplasms 107Esophageal Neoplasms 69Triple Negative Breast Neoplasms 64Stomach Neoplasms 58Fallopian Tube Neoplasms 56Squamous Cell Carcinoma of Head and Neck 52Neoplasm Metastasis 50Head and Neck Neoplasms 44Esophageal Squamous Cell Carcinoma 43Carcinoma, Ovarian Epithelial 42Neoplasms 36Endometrial Neoplasms 34Uterine Cervical Neoplasms 32Recurrence 29Adenocarcinoma Of Esophagus 24Adenocarcinoma of Lung 22Urinary Bladder Neoplasms 21Melanoma 20Carcinoma, Squamous Cell 19Carcinoma 18Small Cell Lung Carcinoma 17Prostatic Neoplasms 15Breast Neoplasms, Male 15Adenocarcinoma, Bronchiolo-Alveolar 13Peritoneal Neoplasms 12Inflammatory Breast Neoplasms 12Testicular Neoplasms 10

Interventions

midostaurin 2pegfilgrastim 1glofitamab 1Topotecan 1Prednisone 1Paclitaxel 1Methylprednisolone 1Immunologic Techniques 1Flow Cytometry 1Clofarabine 1Alemtuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Aggression × Paclitaxel × Clear all
NCT00038545 2018-10-30

A Phase II Study of Paclitaxel and Topotecan With Filgrastim-SD/01 Support For Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma

M.D. Anderson Cancer Center

Phase 2 Completed
25 enrolled
Lymphoid

Aggression, Lymphoma, Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡